IFA 2026: Withings BeamO is getting AI heart and lung analysis in October

Well, this makes BeamO quite a bit more interesting. Withings has used IFA 2026 to announce StethO Sense. This is a new Withings+ feature that will analyse heart and lung sounds recorded by BeamO and return results within seconds from October 1. 

Until now, BeamO could record those sounds, but that was basically where its job ended. You could listen to them yourself or send the recordings to a doctor, but the device and app did not actually tell you what they were hearing.

The stethoscope finally does more than record

That makes StethO Sense a pretty substantial software upgrade. BeamO already combines a thermometer, ECG and digital stethoscope in one handheld device, but the stethoscope was always the part that required someone else to make sense of the data.

We have been following BeamO for a while. It started rolling out in Europe in 2025, adding another unusual health device to a Withings line-up that already includes watches, scales and blood pressure monitors. The hardware was interesting from day one, but StethO Sense starts closing the gap between simply collecting medical-style data at home and getting something immediately useful back from it.

The new feature sits inside the Withings app. You choose whether you want to analyse a heart or lung recording, BeamO guides you through the correct positions on the body, and the analysis comes back within seconds. According to Withings, heart recordings use four standard positions, while lung recordings use six positions for children under 12 and up to eight positions from age 12 upwards.

Two AI systems are doing the listening

Withings is not building all of this analysis itself. StethO Sense combines technology from eMurmur for heart sounds and StethoMe for lung sounds.

eMurmur Heart AI looks for murmurs and sorts recordings into three broad outcomes. It can identify no murmur, an innocent murmur or an abnormal murmur, while also returning heart rate and a confidence score. Withings says the system has shown roughly 90% sensitivity and specificity for detecting pathological murmurs across clinical studies, and the underlying technology has FDA clearance for use with adults and children in the US.

The lung side works a little differently. StethoMe generates a Breathing Index from 0 to 100 using breathing sounds and the overall quality and pattern of breathing. That gives you something much easier to follow than an audio recording sitting in the app with no obvious indication of what you are supposed to be listening for.

There is an important regional distinction here. In the US, StethoMe’s Breathing Index is being offered as a general wellness feature and does not have FDA clearance, while the eMurmur heart analysis does. So although both analyses live inside the same StethO Sense feature, they do not carry the same regulatory status.

There is a subscription catch

StethO Sense will not simply appear as a free BeamO software update. It is part of Withings+, so using the analysis features will require a subscription once any free trial period ends.

Existing BeamO owners who bought the device before October 1 will get a free month of Withings+ when StethO Sense launches. New BeamO buyers will also get a one-month trial. BeamO itself remains priced at around $250 in the US, so anyone buying it specifically for the new AI analysis will need to factor the subscription into the longer-term cost.